

Curriculum vitae

Prof. Dr. Dirk Voitalla

Bayernstrasse 35
40883 Ratingen

Telefon: 02102-964689
E-Mail: D.Voitalla@kkrh.de

Persönliche Daten

Geburtsdatum:	24. August 1964
Geburtsort:	Salzgitter
Familienstand:	verheiratet, zwei Kinder

Wehrdienst, Studium, Ausbildung

07/1977 – 06/1984	Gymnasium Salzgitter, Hochschulreife
07/1984 – 09/1985	Wehrdienst, Luftwaffe in Goslar
09/1985 – 07/1992	Studium der Humanmedizin, Ruhr Universität Bochum
08/1991 – 11/1991	Praktisches Jahr, Dept. of Internal Medicine, Milwaukee, USA,
08/1992 – 06/1994	Facharztausbildung, Neurochirurgische Klinik, Alfried Krupp Krankenhaus, Essen
07/1994 – 11/1995	Facharztausbildung, Psychiatrische Universitätsklinik, Düsseldorf
12/1995 – 11/1998	Facharztausbildung, Neurologische Universitätsklinik, Bochum

Akademischer Werdegang

1998	Promotionsarbeit zum Thema: „Die Bedeutung von Aktivitätsunterschieden der Catechol-O-Methyltransferase (COMT) für das Auftreten motorischer Fluktuationen beim Parkinson Syndrom“, in der Neurologischen Klinik der Ruhr-Universität Bochum unter der Leitung von Professor Przuntek Prädikat: magna cum laude
2006	Habilitation im Fach Neurologie: „Pharmakokinetische Analyse der motorischen Fluktuationen unter Berücksichtigung der Magenentleerung beim idiopathischen Parkinson-Syndrom“
2006	Lehrbefugnis für das Fach Neurologie
2013	Außerplanmäßige Professur der Ruhr-Universität Bochum
2013	Professur für Neurodegeneration im Bereich der Bewegungsstörungen der Ruhr-Universität Bochum

Qualifikationen

1998	Facharzt Neurologie
2005	Zusatzbezeichnung Chirotherapie Zertifikat verkehrsmedizinische Begutachtung
2014	Zertifikat Klinische Prüfungen nach AMG und MPG

Auszeichnungen, Preise, Stipendien

2009	DRG- Preis des Katholischen Klinikums Bochum
2010	Poster Preis der FORUM-Tagung

Klinische Erfahrung

08/1992 – 06/1994	Neurochirurgische Klinik, Alfried Krupp Krankenhaus, Essen
Position:	Assistenzarzt
Verantwortung:	- Patientenversorgung
07/1994 – 11/1995	Psychiatrische Universitätsklinik, Düsseldorf
Position:	Assistenzarzt
Verantwortung:	- Patientenversorgung
12/1995 – 11/1998	Neurologische Universitätsklinik, Bochum
Position:	Assistenzarzt
Verantwortung:	- Patientenversorgung
12/1998 – heute	Neurologische Universitätsklinik, Ruhr-Universität Bochum
Position:	Oberarzt
Verantwortung:	<ul style="list-style-type: none">- Führungsverantwortung als Oberarzt der Station für neurodegenerative Erkrankungen- Führungsverantwortung als Leiter der Ambulanz für Neurodegeneration mit dem Schwerpunkt Parkinson- Personaleinstellungen- Aufbau und Etablierung der Tiefenhirnstimulation in Bochum- Konzeption, Betreuung und Durchführung von Medikamentenstudien- Konzeption, Betreuung und Durchführung von theoretischen Forschungsstudien- Einführung und Betreuung des DRG- Systems als DRG- Verantwortlicher der Klinik- Organisation des Studentenunterrichts im Fach Neurologie im St. Josef Hospital Bochum- Organisation interner und externer Fortbildungsveranstaltungen
10/2007 – 3/2014	Stellvertreter des Klinikdirektors
Seit 4/2014	Chefarzt Neurologische Klinik der Katholischen Kliniken der Ruhrhalbinsel, Essen

Auslandsaufenthalt

1991 Auslandsstudium, University of Wisconsin, USA

Forschungsschwerpunkte

12/1995 – heute Neurologische Universitätsklinik, Ruhr-Universität

Leitungserfahrung

Seit 01.12.1998 Oberarzt der Neurologischen Klinik
Seit 01.08.2001 DRG- Beauftragter der Neurologischen Klinik
Seit 01.10.2007 Stellvertreter des Klinikdirektors; Geschäftsführender Oberarzt

Abschlüsse

02/1994 Approbation
07/1992 3. Staatsexamen Humanmedizin
10/1993 US Medical Licensing Examinations
11/1998 Facharztanerkennung Neurologie
06/1998 Promotion
02/2006 Venia legendi
03/2013 Professur

Promotionstitel: Die Bedeutung von Aktivitätsunterschieden der Catechol-o-Methyltransferase für das Auftreten motorischer Fluktuationen beim M. Parkinson.

Habilitationstitel: Pharmakokinetische Analyse der motorischen Fluktuationen unter Berücksichtigung der Magenentleerung beim idiopathischen Parkinson-Syndrom

Fortbildungsspektrum

- Akupunktur
- Manuelle Medizin
- Psychosomatische Grundversorgung
- Psychotherapie
- Spezielle Schmerztherapie

Studienerfahrung

Celomen,	Phase III,	M. Parkinson, Clinical-Investigator
Celosafe,	Phase III,	M. Parkinson, Clinical-Investigator
RiluPARK,	Phase II,	M. Parkinson, Clinical-Investigator
MOVPark,	Phase III,	M. Parkinson, Principal-Investigator
TULIP,	Phase Ib,	M. Parkinson, Principal-Investigator
SPIRID,	Phase IIb,	M. Parkinson, Principal-Investigator
SPIRID-O,	Phase IIb,	M. Parkinson, Principal-Investigator
EFC5286,	Phase II,	M. Alzheimer, Clinical-Investigator
SR57667B,	Phase II,	M. Alzheimer, Clinical-Investigator
SP1066	Phase IV	M. Parkinson, Principal Investigator
SP0970	Phase IV	M. Parkinson, Wissenschaftlicher Leiter
TevAzi	Phase IV	M. Parkinson, Wissenschaftlicher Leiter
AL108-231	Phase III	Progressive Supranukleäre Paralyse, Principal Investigator
NCT01159691	Phase IV	M. Parkinson, National coordinator
NCT02230904	Phase IV	M. Parkinson, Principal Investigator
NCT02227355	Phase IV	M. Parkinson, Global coordinator
SP1066	Phase IV	M. Parkinson, Clinical-Investigator
AL 108-232	Phase III	PSP, Principal Investigator
PD00013	Phase IV,	M. Parkinson, Global coordinator
PD00018,	Phase IV,	M. Parkinson, Principal-Investigator
BIA-OPC 401,	Phase IV,	M. Parkinson, Principal Investigator
BMS-CN002-012,	Phase III,	PSP
AB13004,	Phase II,	PSP, planned

Tätigkeitsschwerpunkte

- Neurodegenerative Erkrankungen
- Neuroimmunologische Erkrankungen

Publikationen

Allgemeine Publikationen: > 150

Originalarbeiten in Medline gelisteten Zeitschriften: 110

Wissenschaftliche Vorträge: > 250

Mitgliedschaften

Deutsche Parkinson Gesellschaft, Vorstandsmitglied

International Graduate School of Neuroscience Bochum

Deutsche Gesellschaft für Neurologie

Deutsche Gesellschaft für Manuelle Medizin

Deutsche Gesellschaft für autonome Störungen

European Federation of Neurogastroenterology

Forschungsgruppe Akupunktur und Traditionelle Chinesische Medizin

Lehrtätigkeit

1993 -1995

Psychiatrische Universitätsklinik Düsseldorf

1995 – heute

Neurologische Universitätsklinik, Ruhr-Universität Bochum

Essen, den 30.11.2018



Prof. Dr. med. Dirk Voitalla

- Zella S, Kneiphof J, Haghikia A, Gold R, Voitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. *Ther Adv Neurol Disord*. 2018 Oct 26;11: 1756286418805732
- Zella MAS, May C, Müller T, Ahrens M, Tönges L, Gold R, Marcus K, Voitalla D. Landscape of pain in Parkinson's disease: impact of gender differences. *NeurolRes*. 2018 Oct 12:1-11
- Richter D, Voitalla D, Muhlack S, Gold R, Tönges L, Krogias C. Brainstem RapheAlterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients. *Front Neurol*. 2018 Aug 7;9:645..
- Heinzel S, Berg D, Binder S, Ebersbach G, Hickstein L, Herbst H, Lorrain M, Wellach I, Maetzler W, Petersen G, Schmedt N, Volkmann J, Voitalla D, Amelung V. Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? *Front Neurol*. 2018 Jun 29;9:500.
- Voitalla D, Dunac A, Safavi A, Ceravolo MG, Gomez Esteban JC, Pavese N, Asgharnejad M, Joeres L, Schuller JC, Chaudhuri KR. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. *Expert Opin Pharmacother*. 2018 Jun;19(9):937-945.
- Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL; AL-108-231 Investigators. CSF neurofilament light chain and phosphorylated tau181 predict disease progression in PSP. *Neurology*. 2018 Jan 23;90(4):e273-e281.
- Pesch B, Dydak U, Lotz A, Casjens S, Quetscher C, Lehnert M, Abramowski J, Stewig C, Yeh CL, Weiss T, van Thriel C, Herrmann L, Muhlack S, Voitalla D, Glaubitz B, Schmidt-Wilcke T, Brüning T. Association of exposure to manganese and iron with relaxation rates R1 and R2* - magnetic resonance imaging results from the WELDOX II study. *Neurotoxicology*. 2018 Jan;64:68-77.
- Casjens S, Dydak U, Dharmadhikari S, Lotz A, Lehnert M, Quetscher C, Stewig C, Glaubitz B, Schmidt-Wilcke T, Edmondson D, Yeh CL, Weiss T, Thriel CV, Herrmann L, Muhlack S, Voitalla D, Aschner M, Brüning T, Pesch B. Association of exposure to manganese and iron with striatal and thalamic GABA and other neurometabolites - Neuroimaging results from the WELDOX II study. *Neurotoxicology*. 2018 Jan;64:60-67.
- Richter D, Voitalla D, Muhlack S, Gold R, Tönges L, Krogias C. Coronal Transcranial Sonography and M-Mode Tremor Frequency Determination in Parkinson's Disease and Essential Tremor. *J Neuroimaging*. 2017 Apr 20.
- Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, Marx GA, Eloffson J, Tartaglia MC, Litvan I, McGinnis SM, Dickerson BC, Kornak J, Waltzman D, Voltarelli L, Schuff N, Rabinovici GD, Kramer JH, Jack CR Jr, Miller BL, Rosen HJ, Boxer AL; AL-108-231 investigators.. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. *Neurology*. 2016 Nov 8;87(19):2016-2025.
- Moreno Catalá M, Voitalla D, Arampatzis A. Reactive but not predictive locomotor adaptability is impaired in young Parkinson's disease patients. *Gait Posture*. 2016 Jul;48:177-82.
- Buhmann C, Bass H, Hahne M, Jost W, Redecker C, Schwarz M, Voitalla D. [Parkinson's Disease at the Border Between Inpatient and Outpatient Care]. *Fortschr Neurol Psychiatr*. 2016 Jul;84 Suppl 1:S36-40. Recke A, Oei A, Hübner F, Fechner K, Graf J, Hagenah J, May C, Voitalla D, Salmen A, Zillikens D, Gold R, Schlumberger W, Schmidt E. Parkinson's disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. *Br J Dermatol*. 2016 Mar 12.
- Meiser J, Delcambre S, Wegner A, Jäger C, Ghelfi J, d'Herouel AF, Dong X, Weindl D, Stautner C, Nonnenmacher Y, Michelucci A, Popp O, Giesert F, Schildknecht S, Krämer L, Schneider JG, Voitalla D, Wurst W, Skupin A, Weisenhorn DM, Krüger R, Leist M, Hiller K. Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. *Neurobiol Dis*. 2016 May;89:112-25.
- Wüst R, Maurer B, Hauser K, Voitalla D, Sharma M, Krüger R. Mutation analyses and association studies to assess the role of the presenilin-associated rhomboid-like gene in Parkinson's disease. *Neurobiol Aging*. 2016 Mar;39:217.e13-5.
- Henkel S, Wellhausen R, Voitalla D, Marcus K, May C. Epitope Mapping Using Peptide Microarray in Autoantibody Profiling. *Methods Mol Biol*. 2016;1368:209-24.
- Müller T, Baas H, Kassubek J, Riederer P, Urban PP, Schrader C, Reichmann H, Voitalla D, Gerlach M. Laboratory assessments in the course of Parkinson's disease: a clinician's perspective. *J Neural Transm (Vienna)*. 2016 Jan;123(1):65-71.

- Epprecht L, Schreglmann SR, Goetze O, Voitalla D, Baumann CR, Waldvogel D. Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal. *J Neurol*. 2015 Aug;262(8):1946-53.
- Moreno Catalá M, Voitalla D, Arampatzis A. Recovery performance and factors that classify young fallers and non-fallers in Parkinson's disease. *Hum Mov Sci*. 2015 Jun;41:136-46.
- Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. *Lancet Neurol*. 2014 Jul;13(7):676-85.
- Burbulla LF, Fitzgerald JC, Stegen K, Westermeier J, Thost AK, Kato H, Mokranjac D, Sauerwald J, Martins LM, Voitalla D, Rapaport D, Riess O, Proikas-Cezanne T, Rasse TM, Krüger R. Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1. *Cell Death Dis*. 2014 Apr 17;5:e1180.
- Beste C, Kneiphof J, Voitalla D. Effects of fatigue on cognitive control in neurosarcoidosis. *Eur Neuropsychopharmacol*. 2015 Feb 7. pii: S0924-977X(15)00013-9.
- Voitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Grieger F, Müller T. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: A non-interventional prospective multicenter trial. *Parkinsonism Relat Disord*. 2015 Mar;21(3):199-204.
- Kerasnoudis A, Voitalla D, Gold R, Pitarokoili K, Yoon MS. Sarcoid neuropathy: correlation of nerve ultrasound, electrophysiological and clinical findings. *J Neurol Sci*. 2014 Dec 15;347(1-2):129-36.
- Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijssels I, Smolders S, Crosiers D, Corsmit E, Elinck E, Sharma M, Krüger R, Lesage S, Brice A, Chung SJ, Kim MJ, Kim YJ, Ross OA, Wszolek ZK, Rogaeva E, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn PA, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan EK, Zhao Y, Aasly J, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deuschländer A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maraganore DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Van Broeckhoven C; GEO-PD Consortium. Global investigation and meta-analysis of the C9orf72 (G4C2)_n repeat in Parkinson disease. *Neurology*. 2014 Nov 18;83(21):1906-13. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. *Lancet Neurol*. 2014 Jul;13(7):676-85
- Beste C, Kneiphof J, Voitalla D. Modulatory effects of proinflammatory cytokines for action cascading processes - Evidence from neurosarcoidosis. *Brain Behav Immun*. 2014 May 17. pii: S0889-1591(14)00127-5.
- Burbulla LF, Fitzgerald JC, Stegen K, Westermeier J, Thost AK, Kato H, Mokranjac D, Sauerwald J, Martins LM, Voitalla D, Rapaport D, Riess O, Proikas-Cezanne T, Rasse TM, Krüger R. Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1. *Cell Death Dis*. 2014 Apr 17;5:e1180.
- Abel L, Kutschki S, Turewicz M, Eisenacher M, Stoutjesdijk J, Meyer HE, Voitalla D, May C. Autoimmune profiling with protein microarrays in clinical applications. *Biochim Biophys Acta*. 2014 May;1844(5):977-87.
- May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, Brüning T, Pesch B, Stephan C, Voitalla D, Penke B, Janáky T, Virók D, Siklós L, Engelhardt JI, Meyer HE. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. *PLoS One*. 2014 Feb 26;9(2):e89596.
- Zhu JY, Vereshchagina N, Sreekumar V, Burbulla LF, Costa AC, Daub KJ, Voitalla D, Martins LM, Krüger R, Rasse TM. Knockdown of Hsc70-5/mortalin induces loss of synaptic mitochondria in a Drosophila Parkinson's disease model. *PLoS One*. 2013 Dec 30;8(12):e83714.
- Ahrens M, Turewicz M, Casjens S, May C, Pesch B, Stephan C, Voitalla D, Gold R, Brüning T, Meyer HE, Rahnenführer J, Eisenacher M. Detection of patient subgroups with differential expression in omics data: a comprehensive comparison of univariate measures. *PLoS One*. 2013 Nov 22;8(11):e79380.
- Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyrtzi E, Lin CH, Lohmann K, Loriot MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Protective effect

- of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. *Neurobiol Aging*. 2014 Jan;35(1):266.e5-14. doi: 10.1016/j.neurobiolaging.2013.07.013.
- Moreno Catalá M, Voitalla D, Arampatzis A. Central factors explain muscle weakness in young fallers with Parkinson's disease. *Neurorehabil Neural Repair*. 2013 Oct;27(8):753-9.
 - Casjens S, Eckert A, Voitalla D, Ellrichmann G, Turewicz M, Stephan C, Eisenacher M, May C, Meyer HE, Brüning T, Pesch B. Diagnostic value of the impairment of olfaction in Parkinson's disease. *PLoS One*. 2013 May 16;8(5):e64735.
 - Turewicz M, May C, Ahrens M, Voitalla D, Gold R, Casjens S, Pesch B, Brüning T, Meyer HE, Nordhoff E, Böckmann M, Stephan C, Eisenacher M. Improving the default data analysis workflow for large autoimmune biomarker discovery studies with ProtoArrays. *Proteomics*. 2013 Jul;13(14):2083-7.
 - Gröttrup B, Esselmann H, May C, Schrötter A, Voitalla D, Heinsen H, Marcus K, Wiltfang J, Meyer HE, Grinberg LT, Park YM. Challenges in modern biomarker discovery--17th HUPO BPP workshop: May 24-25, 2012, Sao Paulo, Brazil. *Proteomics*. 2013 Jan;13(2):210-6.
 - Brosseron F, May C, Schoenebeck B, Tippler B, Voitalla D, Kauth M, Brockmann K, Meyer HE, Berg D, Bufe A, Marcus K. Stepwise isolation of human peripheral erythrocytes, T lymphocytes, and monocytes for blood cell proteomics. *Proteomics Clin Appl*. 2012 Oct;6(9-10):497-501.
 - Saft C, Andrich J, Fälker M, Gauda S, Küchler S, Voitalla D, Goetze O. No evidence of impaired gastric emptying in early Huntington's Disease. *PLoS Curr*. 2011 Oct 25;3:RRN1284.
 - Müller T, Muhlack S, Voitalla D. Pain perception, pain drug therapy and health status in patients with Parkinson's disease. *Neuroepidemiology*. 2011;37(3-4):183-7.
 - Voitalla D, Goetze O. Treatment approaches of gastrointestinal dysfunction in Parkinson's disease, therapeutical options and future perspectives. *J Neurol Sci*. 2011 Nov 15;310(1-2):152-8.
 - Müller T, Voitalla D, Muhlack S. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. *Naunyn Schmiedebergs Arch Pharmacol*. 2011 Jun;383(6):627-33.
 - Burbulla LF, Schelling C, Kato H, Rapaport D, Voitalla D, Schiesling C, Schulte C, Sharma M, Illig T, Bauer P, Jung S, Nordheim A, Schöls L, Riess O, Krüger R. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. *Hum Mol Genet*. 2010 Nov 15;19(22):4437-52.
 - Petereit HF, Reske D, Tumani H, Jarius S, Markus Leweke F, Voitalla D, Pfister HW, Rubbert A. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. *J Neurol*. 2010 Nov;257(11):1855-63.
 - Müller T, Voitalla D. Quality of life, caregiver burden and insurance in patients with Parkinson's disease in Germany. *Eur J Neurol*. 2010 Nov;17(11):1365-9.
 - Voitalla D, Braak H, Tredici KD, Fogel W, Hagenah J, Oertel W, Berg D. [Transcranial ultrasound in the differential diagnosis of Parkinson's disease]. *Fortschr Neurol Psychiatr*. 2010 Mar;78 Suppl 1:S25-30.
 - Timmermann L, Pauls KA, Wieland K, Jech R, Kurlemann G, Sharma N, Gill SS, Haenggeli CA, Hayflick SJ, Hogarth P, Leenders KL, Limousin P, Malanga CJ, Moro E, Ostrem JL, Revilla FJ, Santens P, Schnitzler A, Tisch S, Valldeoriola F, Vesper J, Volkman J, Voitalla D, Paker S. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. *Brain*. 2010 Mar;133(Pt 3):701-12.
 - Kriebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, Wolburg H, Gizatullina Z, Gellerich FN, Voitalla D, Riess O, Kahle PJ, Proikas-Cezanne T, Krüger R. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. *PLoS One*. 2010 Feb 23;5(2):e9367.
 - Müller T, Voitalla D, Goetze O, Erdmann C. Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. *Mov Disord*. 2008 Jul 30;23(10):1458-61.
 - Müller T, Kolf K, Ander L, Voitalla D, Muhlack S. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. *Clin Neuropharmacol*. 2008 May-Jun;31(3):134-40.
 - Wahl C, Kautzmann S, Kriebiehl G, Strauss K, Voitalla D, Müller T, Bauer P, Riess O, Krüger R. A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients. *J Neural Transm*. 2008 Aug;115(8):1141-8.

- Gerlach M, Hendrich A, Hueber R, Jost W, Winkler J, Woitalla D, Riederer P. Early detection of Parkinson's disease: unmet needs. *Neurodegener Dis.* 2008;5(3-4):137-9.
- Goetze O, Woitalla D. The role of MPTP in Parkinson's disease: connecting brain and gut? *Exp Neurol.* 2008 Apr;210(2):281-5.
- Woitalla D, Mueller T, Russ H, Hock K, Haeger DA. The management approaches to dyskinesia vary from country to country. *Neuroepidemiology.* 2007;29(3-4):163-9. Epub 2007 Nov 27.
- Müller T, Ander L, Kolf K, Woitalla D, Muhlack S. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. *J Neural Transm.* 2007;114(11):1457-62.
- Müller T, Woitalla D, Russ H, Hock K, Haeger DA. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. *J Neural Transm.* 2007;114(8):1023-6.
- Schweitzer KJ, Brüssel T, Leitner P, Krüger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, Berg D. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. *J Neurol.* 2007 May;254(5):613-6.
- Bliem B, Frombach E, Ragert P, Knossalla F, Woitalla D, Tegenthoff M, Dinse HR. Dopaminergic influences on changes in human tactile acuity induced by tactile coactivation. *Exp Brain Res.* 2007 Jul;181(1):131-7. Epub 2007 Mar 8.
- Matusch A, Meyer PT, Bier D, Holschbach MH, Woitalla D, Elmenhorst D, Winz OH, Zilles K, Bauer A. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. *Nucl Med Biol.* 2006 Oct;33(7):891-8.
- Muhlack S, Welnic J, Woitalla D, Muller T. Exercise improves efficacy of levodopa in patients with Parkinson's disease. *Mov Disord.* 2007 Feb 15;22(3):427-30.
- Bliem B, Frombach E, Ragert P, Knossalla F, Woitalla D, Tegenthoff M, DinseHR. Dopaminergic influences on changes in human tactile acuity induced by tactilecoactivation. *Exp Brain Res.* 2007 Jul;181(1):131-7.
- Schweitzer KJ, Brussel T, Leitner P, Kruger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, Berg D. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. *J Neurol.* 2007 May;254(5):613-6.
- Muller T, Ander L, Kolf K, Woitalla D, Muhlack S. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. *J Neural Transm.* 2007 Nov;114(11):1457-62
- Muller T, Woitalla D, Russ H, Hock K, Haeger DA. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. *J Neural Transm.* 2007 Aug;114(8):1023-6
- Muller T, Welnic J, Woitalla D, Muhlack S. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease. *Neurosci Lett.* 2007 Jul 11;422(2):119-22. Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Entacapone improves complex movement performance in patients with Parkinson's disease. *J Clin Neurosci.* 2006 Jun 19;
- Schlitter AM, Woitalla D, Mueller T, Eppelen JT, Dekomien G. The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany. *J Neurol Neurosurg Psychiatry.* 2006 Jul;77(7):891-2.
- Franck T, Krueger R, Woitalla D, Müller T, Engelender S, Riess O. Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease. *J Neural Transm.* 2006 Jun 6;
- Woitalla D, Goetze O, Kim JI, Nikodem AB, Schmidt WE, Przuntek H, Müller T. Levodopa availability improves with progression of Parkinson's disease. *J Neurol.* 2006 Apr 28
- Goetze O, Nikodem AB, Wiezcorek J, Banasch M, Przuntek H, Mueller T, Schmidt WE, Woitalla D. Predictors of gastric emptying in Parkinson's disease. *Neurogastroenterol Motil.* 2006 May;18(5):369-75.
- Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. *Clin Neuropharmacol.* 2006 Mar-Apr;29(2):61-7.
- Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. *J Neural Transm.* 2006 Apr 11

- Schlitter AM, Kurz M, Larsen JP, Voitalla D, Müller T, Epplen JT, Dekomien G. Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts. *Acta Neurol Scand.* 2006 Jan;113(1):9-13.
- Schlitter AM, Kurz M, Larsen JP, Voitalla D, Mueller T, Epplen JT, Dekomien G. Exclusion of PINK1 as candidate gene for the late-onset form of Parkinson's disease in two European populations. *J Negat Results Biomed.* 2005 Dec 14;4:10.
- Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Voitalla D. Inhibition of catechol-O-methyltransferase contributes to more stable Levodopa plasma levels. *Mov Disord.* 2006 Mar;21(3):332-6.
- Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, Schmitz-Hubsch T, Klein C, Tan EK, Schols L, Marsh L, Dawson TM, Janetzky B, Müller T, Voitalla D, Kostic V, Pramstaller PP, Oertel WH, Bauer P, Krueger R, Gasser T, Riess O. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. *Mov Disord.* 2005 Sep;20(9):1191-4.
- Goetze O, Wiczorek J, Mueller T, Przuntek H, Schmidt WE, Voitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using ¹³C-sodium octanoate breath test. *Neurosci Lett.* 2005 Mar 3;375(3):170-3.
- Hering R, Strauss KM, Tao X, Bauer A, Voitalla D, Mietz EM, Petrovic S, Bauer P, Schaible W, Müller T, Schols L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, Tong L, Krüger R, Riess O. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). *Hum Mutat.* 2004 Oct;24(4):321-9.
- Voitalla D, Müller T, Benz S, Horowski R, Przuntek H. Transdermal lisuride delivery in the treatment of Parkinson's disease. *J Neural Transm Suppl.* 2004;(68):89-95.
- Müller T, Benz S, Bornke Ch, Muhlack S, Voitalla D, Przuntek H. Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson's disease. *J Neural Transm Suppl.* 2004;(68):79-87.
- Muhlack S, Konietzka S, Voitalla D, Przuntek H, Müller T. Simple movement sequences better correlate to levodopa plasma levels than complex ones. *J Neural Transm Suppl.* 2004;(68):53-60.
- Glass AS, Huynh DP, Franck T, Voitalla D, Müller T, Pulst SM, Berg D, Krüger R, Riess O. Screening for mutations in synaptotagmin XI in Parkinson's disease. *J Neural Transm Suppl.* 2004;(68):21-8.
- Voitalla D, Kuhn W, Müller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. *J Neural Transm Suppl.* 2004;(68):15-20.
- Muhlack S, Voitalla D, Welnic J, Twiehaus S, Przuntek H, Müller T. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. *Neurosci Lett.* 2004 Jun 17;363(3):284-7.
- Hering R, Petrovic S, Mietz EM, Holzmann C, Berg D, Bauer P, Voitalla D, Müller T, Berger K, Krüger R, Riess O. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. *Neurology.* 2004 Apr 13;62(7):1231-2.
- Krüger R, Fischer C, Schulte T, Strauss KM, Müller T, Voitalla D, Berg D, Hungs M, Gobbele R, Berger K, Epplen JT, Riess O, Schols L. Mutation analysis of the neurofilament M gene in Parkinson's disease. *Neurosci Lett.* 2003 Nov 13;351(2):125-9.
- Sprengelmeyer R, Young AW, Mahn K, Schroeder U, Voitalla D, Buttner T, Kuhn W, Przuntek H. Facial expression recognition in people with medicated and unmedicated Parkinson's disease. *Neuropsychologia.* 2003;41(8):1047-57.
- Müller T, Voitalla D, Kuhn W. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. *J Neurol Neurosurg Psychiatry.* 2003 Apr;74(4):549.
- Müller T, Voitalla D, Fowler B, Kuhn W. 3-OMD and homocysteine plasma levels in parkinsonian patients. *J Neural Transm.* 2002 Feb;109(2):175-9.
- Schulte T, Schols L, Müller T, Voitalla D, Berger K, Krüger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. *Neurosci Lett.* 2002 Jun 21;326(1):70-2.
- Sickmann A, Dormeyer W, Wortelkamp S, Voitalla D, Kuhn W, Meyer HE. Towards a high resolution separation of human cerebrospinal fluid. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2002 May 5;771(1-2):167-96.
- Müller T, Voitalla D, Peters S, Kohla K, Przuntek H. Progress of visual dysfunction in Parkinson's disease. *Acta Neurol Scand.* 2002 Apr;105(4):256-60.
- Krüger R, Schols L, Müller T, Kuhn W, Voitalla D, Przuntek H, Epplen JT, Riess O. Evaluation of the gamma-synuclein gene in German Parkinson's disease patients. *Neurosci Lett.* 2001 Sep 14;310(2-3):191-3.

- Müller T, Voitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. *Neurosci Lett.* 2001 Jul 27;308(1):54-6.
- Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Müller T, Voitalla D, Portman AT, Maguire RP, Veenma L, Schroder U, Schols L, Epplen JT, Riess O, Przuntek H. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. *Neurology.* 2001 May 22;56(10):1355-62.
- Kuhn W, Hummel T, Voitalla D, Müller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. *Neurology.* 2001 Jan 23;56(2):281;
- Voitalla D, Henkes H, Felber S, Weber W, Janisch W, Kuhne D. Clinical aspects and diagnostic imaging in sarcoidosis of the nervous system *Radiologe.* 2000 Nov;40(11):1064-76.
- Weber W, Henkes H, Felber S, Janisch W, Voitalla D, Kuhne D. Septic-embolic and septic metastatic brain abscess *Radiologe.* 2000 Nov;40(11):1017-28.
- Krüger R, Hardt C, Tschentscher F, Jackel S, Kuhn W, Müller T, Werner J, Voitalla D, Berg D, Kuhn N, Fuchs GA, Santos EJ, Przuntek H, Epplen JT, Schols L, Riess O. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. *J Neural Transm.* 2000;107(5):553-62.
- Sickmann A, Dormeyer W, Wortelkamp S, Voitalla D, Kuhn W, Meyer HE. Identification of proteins from human cerebrospinal fluid, separated by two-dimensional polyacrylamide gel electrophoresis. *Electrophoresis.* 2000 Jul;21(13):2721-8.
- Krüger R, Menezes-Saecker AM, Schols L, Kuhn W, Müller T, Voitalla D, Berg D, Berger K, Przuntek H, Epplen JT, Riess O. Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. *Neuroreport.* 2000 Aug 3;11(11):2439-42.
- Wintermeyer P, Krüger R, Kuhn W, Müller T, Voitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schols L, Epplen JT, Riess O. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. *Neuroreport.* 2000 Jul 14;11(10):2079-82.
- Müller T, Voitalla D, Hunsdiek A, Kuhn W. Elevated plasma levels of homocysteine in dystonia. *Acta Neurol Scand.* 2000 Jun;101(6):388-90.
- Müller T, Voitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. *Parkinsonism Relat Disord.* 2000 Jul 1;6(3):171-173.
- Müller T, Voitalla D, Schulz D, Peters S, Kuhn W, Przuntek H. Tolcapone increases maximum concentration of levodopa. *J Neural Transm.* 2000;107(1):113-9.
- Voitalla D, Karwasz R, Müller T, Przuntek H, Kuhn W. The activity of catechol-O-methyltransferase in parkinsonian patients with "on-off fluctuations". *J Neural Transm.* 2000;107(1):105-11.
- Russ H, Müller T, Voitalla D, Rahbar A, Hahn J, Kuhn W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. *Naunyn Schmiedebergs Arch Pharmacol.* 1999 Dec;360(6):719-20.
- Krüger R, Vieira-Saecker AM, Kuhn W, Berg D, Müller T, Kuhn N, Fuchs GA, Storch A, Hungs M, Voitalla D, Przuntek H, Epplen JT, Schols L, Riess O. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. *Ann Neurol.* 1999 May;45(5):611-7.
- Krüger R, Vieira-Saecker AM, Kuhn W, Müller T, Voitalla D, Schols L, Przuntek H, Epplen JT, Riess O. Analysis of the parkin deletion in sporadic and familial Parkinson's disease. *J Neural Transm.* 1999;106(2):159-63.
- Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Voitalla D, Müller T. Elevated plasma levels of homocysteine in Parkinson's disease. *Eur Neurol.* 1998 Nov;40(4):225-7.
- Kuhn W, Voitalla D, Gerlach M, Russ H, Müller T. Tolcapone and neurotoxicity in Parkinson's disease. *Lancet.* 1998 Oct 17;352(9136):1313-4.
- Müller T, Sallstrom Baum S, Haussermann P, Voitalla D, Rommelspacher H, Przuntek H, Kuhn W. Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patients. *J Neural Transm.* 1998;105(2-3):239-46.
- Kuhn W, Winkel R, Voitalla D, Meves S, Przuntek H, Müller T. High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries. *Neurology.* 1998 Jun;50(6):1885-6.

- Krüger R, Kuhn W, Müller T, Voitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat Genet.* 1998 Feb;18(2):106-8
- Voitalla D, Klieser E. Psychiatric diseases with onset in puerperium *Gynäkologe.* 1995 Dec;28(6):434-9.